Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer subtypes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709026 | PMC |
| http://dx.doi.org/10.1158/2159-8290.CD-15-1352 | DOI Listing |
Publication Analysis
Top Keywords
trk inhibitors
8
lmna-ntrk1 fusion
8
tracking response
4
response resistance
4
resistance trk
4
inhibitors studies
4
studies validate
4
validate lmna-ntrk1
4
fusion oncogenic
4
oncogenic driver
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!